Clinical trial
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered…
NCT00347555 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00347555 |
|---|---|
| Title | Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly |
| Official title | Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Plasmodium Falciparum Malaria |
| Intervention type | Biological, Drug |
| Interventions | Aluminum Phosphate, Placebo, EBA-175 RII-NG Malaria Vaccine |
| Enrollment | 80 |
| Start date | May 1, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Jul 4, 2006 |
| Last update posted | Apr 12, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: